Future research directions should focus on: (i) the development of highly selective small-molecule inhibitors or novel nucleic acid–based therapeutics; (ii) integrated analyses using transcriptomics, proteomics, and single-cell omics to dissect METTL1 function across distinct immune cell populations; and (iii) rational combination strategies to achieve precision and individualized cancer therapy. Here, METTL1 is linked to cancer.